CRISPR Therapeutics AG (CRSP) Non-Current Assets (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Non-Current Assets data on file, last reported at $277.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 7.05% year-over-year to $277.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (down 6.09% YoY), and the FY2025 full-year result was $279.6 million, down 8.31% from the prior year.
• Non-Current Assets slipped to $277.5 million in Q1 2026, from $279.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $420.7 million in Q3 2022 to a low of $277.5 million in Q1 2026.
• A 5-year average of $327.5 million and a median of $321.5 million in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets soared 175.23% in 2022 and declined 22.44% in 2023, its largest moves.
• Tracing CRSP's Non-Current Assets over 5 years: stood at $390.0 million in 2022, then retreated by 17.57% to $321.5 million in 2023, then fell by 5.16% to $304.9 million in 2024, then slipped by 8.31% to $279.6 million in 2025, then slipped by 0.76% to $277.5 million in 2026.
• Business Quant data shows CRSP's Non-Current Assets at $277.5 million in Q1 2026, $279.6 million in Q4 2025, and $316.2 million in Q3 2025.